Allergy Asthma Respir Dis.  2017 Jan;5(1):41-46. 10.4168/aard.2017.5.1.41.

Genetic polymorphisms of interleukin-10 and transforming growth factor-β1 and antituberculosis drugs-induced liver injury

• Jung S
• Kim SH
• Sohn JW
• Yoon HJ
• Shin DH
• Jee YK
• Kim SH

• KMID: 2368575
• DOI: http://doi.org/10.4168/aard.2017.5.1.41

Abstract

PURPOSE
Drug-induced liver injury is one of the serious adverse reactions resulting in severe morbidity and discontinuation of medications. Previously, IL-10 gene polymorphism has been reported to be associated with diclofenac-induced hepatitis. In this study, we aimed to investigate the associations between genetic polymorphisms of immune-regulating cytokines (IL-10 and TGF-β1) with antituberculosis drugs (ATD)-induced liver injury.
METHODS
We enrolled 80 patients with ATD-induced liver injury and 238 ATD-tolerant controls. Two single nucleotide polymorphisms (SNP) of IL-10 (-1082A>G, rs1800896; -819T>C, rs1800871) and one promoter SNP of TGF-β1 gene (-509C>T, rs1800469) were genotyped in both groups. Genotype frequencies of these SNPs were compared between case and control groups.
RESULTS
In 2 promoter SNPs of IL-10 gene, there was no significant difference of genotype frequencies between patients with ATD-induced liver injury and controls. In addition, the genotype frequency of TGF-β1 -509C>T SNP in ATD-induced liver injury patients were not different from those of controls.
CONCLUSION
In conclusion, there was no significant association between IL-10 and TGF-β1 gene polymorphisms and ATD-induced liver injury. These findings suggest that IL-10 and TGF-β1 do not play important role in the development of ATD-induced liver injury.

Keyword

Antitubercular agents; Drug-induced liver injury; Interleukin-10; Transforming growth factor beta1; Genetic polymorphism

MeSH Terms

Antitubercular Agents
Cytokines
Drug-Induced Liver Injury
Genotype
Hepatitis
Humans
Interleukin-10*
Liver*
Polymorphism, Genetic*
Polymorphism, Single Nucleotide
Transforming Growth Factor beta1
Antitubercular Agents
Cytokines
Interleukin-10
Transforming Growth Factor beta1

Reference

1. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167:603–662.

2. Tahaoğlu K, Ataç G, Sevim T, Tärün T, Yazicioğlu O, Horzum G, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2001; 5:65–69.

3. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010; 52:2065–2076.

4. Kwon H, Lee SH, Kim SE, Lee JH, Jee YK, Kang HR, et al. Spontaneously reported hepatic adverse drug events in Korea: multicenter study. J Korean Med Sci. 2012; 27:268–273.

5. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008; 23:192–202.

6. Huang YS. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc. 2014; 77:169–173.

7. Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics. 2009; 10:1767–1779.

8. Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis. 2009; 29:383–392.

9. Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int. 2015; 35:1801–1808.

10. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004; 39:1430–1440.

11. Pachkoria K, Lucena MI, Crespo E, Ruiz-Cabello F, Lopez-Ortega S, Fernandez MA, et al. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol. 2008; 49:107–114.

12. Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, et al. TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. Liver Int. 2012; 32:809–814.

13. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174:935–952.

14. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther. 2011; 89:911–914.

15. Metushi IG, Zhu X, Chen X, Gardam MA, Uetrecht J. Mild isoniazid-induced liver injury in humans is associated with an increase in Th17 cells and T cells producing IL-10. Chem Res Toxicol. 2014; 27:683–689.

16. Perwitasari DA, Atthobari J, Wilffert B. Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug Metab Rev. 2015; 47:222–228.

17. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002; 166:916–919.

18. Chen R, Zhang Y, Tang S, Lv X, Wu S, Sun F, et al. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study. J Clin Pharm Ther. 2015; 40:110–115.

19. Wang J, Chen R, Tang S, Lv X, Wu S, Zhang Y, et al. Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control study. PLoS One. 2015; 10:e0118862.

20. de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE. Interleukin-10. Curr Opin Immunol. 1992; 4:314–320.

21. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology. 2000; 118:655–660.

22. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol. 1999; 7:127–128.

23. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997; 24:1–8.

24. Ouyang L, Lv YD, Hou C, Wu GB, He ZH. Quantitative analysis of the association between interleukin-10 1082A/G polymorphism and susceptibility to sepsis. Mol Biol Rep. 2013; 40:4327–4332.

25. Cai F, Cui N, Ma H, Wang X, Qiao G, Liu D. Interleukin-10 -1082A/G polymorphism is associated with the development of acute pancreatitis in a Chinese population. Int J Clin Exp Pathol. 2015; 8:15170–15176.

26. Wang J, Chen R, Tang S, Lv X, Wu S, Zhang Y, et al. Interleukin-4 and interleukin-10 polymorphisms and antituberculosis drug-induced hepatotoxicity in Chinese population. J Clin Pharm Ther. 2015; 40:186–191.

27. Michalopoulos GK. Liver regeneration: molecular mechanisms of growth control. FASEB J. 1990; 4:176–187.

28. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342:1350–1358.

29. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994; 331:1286–1292.

30. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 1993; 328:1828–1835.

31. Mohy A, Fouad A. Role of transforming growth factor-β1 in serum and -509 C>T promoter gene polymorphism in development of liver cirrhosis in Egyptian patients. Meta Gene. 2014; 2:631–637.

32. Xiang TX, Cheng N, Li XN, Wu XP. Association between transforming growth factor-β1 polymorphisms and hepatocellular cancer risk: a meta-analysis. Hepatol Res. 2012; 42:583–590.

33. Park HW. Interpretation of negative results in genetic epidemiology. Allergy Asthma Respir Dis. 2015; 3:93–94.